The biggest-selling drugs of 2023
Move over Comirnaty: Keytruda takes top spot as its indications broaden and demand for Covid vaccines recedes.
The biggest-selling pharma companies of 2023
Propelled by Covid Pfizer surges ahead, but more interest could fall on a cohort of companies driven by newcomer drugs lower down the list.
Amgen strikes out for the Horizon
Amgen sees off Sanofi and J&J to clinch the rare disease player for $28bn, ensuring that the M&A year ends with a bang.
Burned by Palforzia, Nestlé retreats from its pharma experiment
The chocolate-to-vitamins giant discovers that launching a drug is hard. Should its biopharma partners be worried?
Ash 2022 preview – Brukinsa has the edge over Calquence
Brukinsa’s head-to-head victory over Imbruvica is confirmed, and the Beigene BTK inhibitor looks better than Calquence too.
Novartis’s renaissance gets off to a false start
Leqvio’s launch remains sluggish and tislelizumab looks even more like a dead end in the US.
